MasterMetals on Twitter

April 17, 2015

ReNeuron heartened by stroke trial data

Shares in ReNeuron (LON:RENE) rose sharply following an update on a Phase I clinical trial of ReNeuron’s CTX stem cell therapy for disabled stroke patients. There have been no cell-related or...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]] @MasterMetals MasterMetals Blog

No comments:

Post a Comment

Commented on The MasterMetals BlogThe MasterMetals Blog